

**Blood transfusion therapy**

COMPONENT	DOSAGE EFFECT	CLINICAL USE
<b>Packed RBCs</b>	↑ Hb and O <sub>2</sub> binding (carrying) capacity	Acute blood loss, severe anemia
<b>Platelets</b>	↑ platelet count (↑ ~ 5000/mm <sup>3</sup> /unit)	Stop significant bleeding (thrombocytopenia, qualitative platelet defects)
<b>Fresh frozen plasma/ prothrombin complex concentrate</b>	↑ coagulation factor levels; FFP contains all coagulation factors and plasma proteins; PCC generally contains factors II, VII, IX, and X, as well as protein C and S	Cirrhosis, immediate anticoagulation reversal
<b>Cryoprecipitate</b>	Contains fibrinogen, factor VIII, factor XIII, vWF, and fibronectin	Coagulation factor deficiencies involving fibrinogen and factor VIII
<b>Albumin</b>	↑ intravascular volume and oncotic pressure	Post-paracentesis, therapeutic plasmapheresis

Blood transfusion risks include infection transmission (low), transfusion reactions, iron overload (may lead to 2° hemochromatosis), hypocalcemia (citrate is a Ca<sup>2+</sup> chelator), and hyperkalemia (RBCs may lyse in old blood units).

**Leukemia vs lymphoma**

<b>Leukemia</b>	Lymphoid or myeloid neoplasm with widespread involvement of bone marrow. Tumor cells are usually found in peripheral blood.
<b>Lymphoma</b>	Discrete tumor mass arising from lymph nodes. Variable clinical presentation (eg, arising in atypical sites, leukemic presentation).

**Hodgkin vs non-Hodgkin lymphoma****Hodgkin****Non-Hodgkin**

Both may have constitutional (“B”) signs/symptoms: low-grade fever, night sweats, weight loss.

Localized, single group of nodes with contiguous spread (stage is strongest predictor of prognosis). Better prognosis.

Multiple lymph nodes involved; extranodal involvement common; noncontiguous spread. Worse prognosis.

Characterized by Reed-Sternberg cells.

Majority involve B cells; rarely of T-cell lineage.

Bimodal distribution: young adults, > 55 years.


Can occur in children and adults.

Associated with EBV.

May be associated with autoimmune diseases and viral infections (eg, HIV, EBV, HTLV).

**Hodgkin lymphoma**



Contains Reed-Sternberg cells: distinctive tumor giant cells; bilobed nucleus with the **2** halves as mirror images (“owl eyes” **A**). RS cells are CD**15**+ and CD**30**+ B-cell origin. **2** owl eyes × **15** = **30**.




SUBTYPE	NOTES
Nodular sclerosis	Most common
Mixed cellularity	Eosinophilia; seen in immunocompromised patients
Lymphocyte <b>rich</b>	<b>Best</b> prognosis (the <b>rich</b> have <b>better</b> bank accounts)
Lymphocyte <b>depleted</b>	<b>Worst</b> prognosis (the <b>poor</b> have <b>worse</b> bank accounts); seen in immunocompromised patients

## Non-Hodgkin lymphoma

TYPE	OCCURS IN	GENETICS	COMMENTS
Neoplasms of mature B cells			
<b>Burkitt lymphoma</b>	Adolescents or young adults	t(8;14)—translocation of <i>c-myc</i> (8) and heavy-chain Ig (14)	“ <b>Starry sky</b> ” appearance ( <b>StarBurst</b> ), sheets of lymphocytes with interspersed “tingible body” macrophages (arrows in <b>A</b> ). Associated with EBV. Jaw lesion <b>B</b> in endemic form in Africa; pelvis or abdomen in sporadic form.
<b>Diffuse large B-cell lymphoma</b>	Usually older adults, but 20% in children	Mutations in <i>BCL-2</i> , <i>BCL-6</i>	Most common type of non-Hodgkin lymphoma in adults.
<b>Follicular lymphoma</b>	Adults	t(14;18)—translocation of heavy-chain Ig (14) and <i>BCL-2</i> (18)	Indolent course with painless “waxing and waning” lymphadenopathy. Bcl-2 normally inhibits apoptosis.
<b>Mantle cell lymphoma</b>	Adult <b>males</b> >> adult females	t(11;14)—translocation of cyclin D1 (11) and heavy-chain Ig (14), CD5+	Very aggressive, patients typically present with late-stage disease.
<b>Marginal zone lymphoma</b>	Adults	t(11;18)	Associated with chronic inflammation (eg, Sjögren syndrome, chronic gastritis [MALT lymphoma; may regress with <i>H pylori</i> eradication]).
<b>Primary central nervous system lymphoma</b>	Adults	EBV related; associated with HIV/AIDS	Considered an AIDS-defining illness. Variable presentation: confusion, memory loss, seizures. CNS mass (often single, ring-enhancing lesion on MRI) in immunocompromised patients <b>C</b> , needs to be distinguished from toxoplasmosis via CSF analysis or other lab tests.
Neoplasms of mature T cells			
<b>Adult T-cell lymphoma</b>	Adults	Caused by HTLV (associated with IV drug use)	Adults present with cutaneous lesions; common in Japan ( <b>T</b> -cell in <b>T</b> okyo), West Africa, and the Caribbean. Lytic bone lesions, hypercalcemia.
<b>Mycosis fungoides/Sézary syndrome</b>	Adults		Mycosis fungoides: skin patches and plaques <b>D</b> (cutaneous T-cell lymphoma), characterized by atypical CD4+ cells with “cerebriform” nuclei and intraepidermal neoplastic cell aggregates (Pautrier microabscess). May progress to Sézary syndrome (T-cell leukemia).



**Plasma cell disorders**

Characterized by monoclonal immunoglobulin (paraprotein) overproduction due to plasma cell disorder.

Labs: serum protein electrophoresis (SPEP) or free light chain (FLC) assay for initial tests (M spike on SPEP represents overproduction of a monoclonal Ig fragment). For urinalysis, use 24-hr urine protein electrophoresis (UPEP) to detect light chain, as routine urine dipstick detects only albumin.

Confirm with bone marrow biopsy.

**Multiple myeloma**

Overproduction of IgG (55% of cases) > IgA.

Clinical features: **CRAB**

- Hyper**C**alcemia (↑ secretion of cytokines [eg, IL-1, TNF-α, RANK-L] by malignant plasma cells → ↑ osteoclast activity)
- **R**enal involvement
- **A**nemia
- **B**one lytic lesions (“punched out” on X-ray **A**) → back pain.

Peripheral blood smear shows rouleaux formation **B** (RBCs stacked like poker chips).

Urinalysis shows Ig light chains (Bence Jones proteinuria) with ⊖ urine dipstick.

Bone marrow analysis shows > 10% monoclonal plasma cells with clock-face chromatin **C** and intracytoplasmic inclusions containing IgG.

Complications: ↑ infection risk, 1° amyloidosis (AL).

**Waldenstrom macroglobulinemia**

Overproduction of Ig**M** (**macro**globulinemia because Ig**M** is the **largest** Ig).

Clinical features:

- Peripheral neuropathy
- No CRAB findings
- Hyperviscosity syndrome:
  - Headache
  - Blurry vision
  - Raynaud phenomenon
  - Retinal hemorrhages

Bone marrow analysis shows > 10% small lymphocytes with intranuclear pseudoinclusions containing IgM (lymphoplasmacytic lymphoma).

Complication: thrombosis.


**Monoclonal gammopathy of undetermined significance**


Overproduction of any Ig type.

Usually asymptomatic. No CRAB findings.

Bone marrow analysis shows < 10% monoclonal plasma cells.

Complication: 1–2% risk per year of transitioning to multiple myeloma.



**Myelodysplastic syndromes**

Stem cell disorders involving ineffective hematopoiesis → defects in cell maturation of nonlymphoid lineages. Bone marrow blasts < 20% (vs > 20% in AML). Caused by de novo mutations or environmental exposure (eg, radiation, benzene, chemotherapy). Risk of transformation to AML. More common in older adults.

**Pseudo-Pelger-Huët anomaly**—neutrophils with bilobed (“duet”) nuclei **A**. Associated with myelodysplastic syndromes or drugs (eg, immunosuppressants).

**Leukemias**

Unregulated growth and differentiation of WBCs in bone marrow → marrow failure → anemia (↓ RBCs), infections (↓ mature WBCs), and hemorrhage (↓ platelets). Usually presents with ↑ circulating WBCs (malignant leukocytes in blood), although some cases present with normal/↓ WBCs.

Leukemic cell infiltration of liver, spleen, lymph nodes, and skin (leukemia cutis) possible.

TYPE	NOTES
------	-------

**Lymphoid neoplasms****Acute lymphoblastic leukemia/lymphoma**

Most frequently occurs in children; less common in adults (worse prognosis). T-cell ALL can present as mediastinal mass (presenting as SVC-like syndrome). Associated with Down syndrome. Peripheral blood and bone marrow have ↑↑↑ lymphoblasts **A**.

TdT+ (marker of pre-T and pre-B cells), CD10+ (marker of pre-B cells).

Most responsive to therapy.

May spread to CNS and testes.

t(12;21) → better prognosis; t(9;22) (Philadelphia chromosome) → worse prognosis.

**Chronic lymphocytic leukemia/small lymphocytic lymphoma**

Age > 60 years. Most common adult leukemia. CD20+, CD23+, CD5+ B-cell neoplasm. Often asymptomatic, progresses slowly; smudge cells **B** in peripheral blood smear; autoimmune hemolytic anemia. **CLL** = **C**rushed **L**ittle **L**ymphocytes (smudge cells).

Richter transformation—CLL/SLL transformation into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL).

**Hairy cell leukemia**

Adult males. Mature B-cell tumor. Cells have filamentous, hairlike projections (fuzzy appearing on LM **C**). Peripheral lymphadenopathy is uncommon.

Causes marrow fibrosis → dry tap on aspiration. Patients usually present with massive splenomegaly and pancytopenia.

Stains **TRAP** (Tartrate-Resistant Acid Phosphatase) ⊕ ('**TRAP**ped in a **hairy** situation'). TRAP stain largely replaced with flow cytometry. Associated with *BRAF* mutations.

Treatment: purine analogs (cladribine, pentostatin).

**Myeloid neoplasms****Acute myelogenous leukemia**

Median onset 65 years. Auer rods **D**; myeloperoxidase ⊕ cytoplasmic inclusions seen mostly in APL (formerly M3 AML); ↑↑↑ circulating myeloblasts on peripheral smear. May present with leukostasis (capillary occlusion by malignant, nondistensible cells → organ damage).


Risk factors: prior exposure to alkylating chemotherapy, radiation, benzene, myeloproliferative disorders, Down syndrome (typically acute megakaryoblastic leukemia [formerly M7 AML]).

APL: t(15;17), responds to all-*trans* retinoic acid (vitamin A) and arsenic trioxide, which induce differentiation of promyelocytes; DIC is a common presentation.

**Chronic myelogenous leukemia**

Peak incidence: 45–85 years; median age: 64 years. Defined by the Philadelphia chromosome (t[9;22], *BCR-ABL*) and myeloid stem cell proliferation. Presents with dysregulated production of mature and maturing granulocytes (eg, neutrophils, metamyelocytes, myelocytes, basophils **E**) and splenomegaly. May accelerate and transform to AML or ALL ("blast crisis").

Responds to *BCR-ABL* tyrosine kinase inhibitors (eg, imatinib).









**Myeloproliferative neoplasms**

Malignant hematopoietic neoplasms with varying impacts on WBCs and myeloid cell lines.

<b>Polycythemia vera</b>	Primary polycythemia. Disorder of ↑ RBCs, usually due to acquired <i>JAK2</i> mutation. May present as intense itching after shower (aquagenic pruritus). Rare but classic symptom is erythromelalgia (severe, burning pain and red-blue coloration) due to episodic blood clots in vessels of the extremities <b>A</b> . Associated with hyperviscosity and thrombosis (eg, PE, DVT, Budd-Chiari syndrome). ↓ EPO (vs 2° polycythemia, which presents with endogenous or artificially ↑ EPO). Treatment: phlebotomy, hydroxyurea, ruxolitinib ( <i>JAK1/2</i> inhibitor).				
<b>Essential thrombocythemia</b>	Characterized by massive proliferation of megakaryocytes and platelets. Symptoms include bleeding and thrombosis. Blood smear shows markedly increased number of platelets, which may be large or otherwise abnormally formed <b>B</b> . Erythromelalgia may occur.				
<b>Myelofibrosis</b>	Atypical megakaryocyte hyperplasia → ↑ TGF-β secretion → ↑ fibroblast activity → obliteration of bone marrow with fibrosis <b>C</b> . Associated with massive splenomegaly and “teardrop” RBCs <b>D</b> . “Bone marrow <b>cries</b> because it’s fibrosed and is a dry tap.”				
	RBCs	WBCs	PLATELETS	PHILADELPHIA CHROMOSOME	<i>JAK2</i> MUTATIONS
Polycythemia vera	↑	↑	↑	⊖	⊕
Essential thrombocythemia	—	—	↑	⊖	⊕ (30–50%)
Myelofibrosis	↓	Variable	Variable	⊖	⊕ (30–50%)
CML	↓	↑	↑	⊕	⊖

**Leukemoid reaction vs chronic myelogenous leukemia**

	<b>Leukemoid reaction</b>	<b>Chronic myelogenous leukemia</b>
DEFINITION	Reactive neutrophilia > 50,000 cells/mm <sup>3</sup>	Myeloproliferative neoplasm ⊕ for <i>BCR-ABL</i>
NEUTROPHIL MORPHOLOGY	Toxic granulation, Döhle bodies, cytoplasmic vacuoles	Pseudo-Pelger-Huët anomaly
LAP SCORE	↑	↓ (LAP enzyme ↓ in malignant neutrophils)
EOSINOPHILS AND BASOPHILS	Normal	↑

**Polycythemia**

	PLASMA VOLUME	RBC MASS	O <sub>2</sub> SATURATION	EPO LEVELS	ASSOCIATIONS
Relative	↓	—	—	—	Dehydration, burns.
Appropriate absolute	—	↑	↓	↑	Lung disease, congenital heart disease, high altitude, obstructive sleep apnea.
Inappropriate absolute	—	↑	—	↑	Exogenous EPO (athlete misuse, also called “blood doping”), androgen supplementation. Inappropriate EPO secretion: malignancy (eg, RCC, HCC).
Polycythemia vera	↑	↑↑	—	↓	EPO ↓ in PCV due to negative feedback suppressing renal EPO production.

↑↓ = 1° disturbance

**Chromosomal translocations**

TRANSLOCATION	ASSOCIATED DISORDER	NOTES
t(8;14)	Burkitt (Burk-8) lymphoma ( <i>c-myc</i> activation)	The Ig heavy chain genes on chromosome 14 are constitutively expressed. When other genes (eg, <i>c-myc</i> and <i>BCL-2</i> ) are translocated next to this heavy chain gene region, they are overexpressed.
t(11;14)	Mantle cell lymphoma (cyclin D1 activation)	
t(11;18)	Marginal zone lymphoma	
t(14;18)	Follicular lymphoma ( <i>BCL-2</i> activation)	
t(15;17)	APL (formerly M3 type of AML)	
t(9;22) ( <b>Philadelphia chromosome</b> )	<b>CML</b> ( <i>BCR-ABL</i> hybrid), ALL (less common); <b>Philadelphia</b> Crea <b>ML</b> cheese	

**Langerhans cell histiocytosis**

Collective group of proliferative disorders of Langerhans cells (antigen-presenting cells normally found in the skin). Presents in a child as lytic bone lesions **A** and skin rash or as recurrent otitis media with a mass involving the mastoid bone. Cells are functionally immature and do not effectively stimulate primary T cells via antigen presentation. Cells express S-100 and CD1a. Birbeck granules (“tennis rackets” or rod shaped on EM) are characteristic **B**.

